• The Joint forecasts 2026 system-wide sales of $508 million to $512 million, versus $532.4 million in 2025.
• Comparable sales are expected to decline 2.5% to 3.5%, versus a 0.4% decline in 2025.
• Consolidated adjusted EBITDA guidance remains $12.5 million to $13.5 million, compared with $13 million in 2025.
• Year-end clinic count is expected to fall approximately 50 from year-end 2025 as the portfolio shifts toward stronger operators and healthier sites.
• Third-quarter system-wide sales fell 3.1% to $123.3 million; comparable sales declined 1.9%, improving 90 basis points from the second quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Joint Corp. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.